OXB Oxford BioMedica PLC

Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD

Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD
EN
06/10/2020

Underlying

OXBOxford BioMedica PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oxford BioMedica PLC

Free Trial
OXB Oxford BioMedic...

Oxford BioMedica: 1 director

A director at Oxford BioMedica bought 11,389 shares at 324p and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

OXB OXFORD BIOMEDICA PLC
06/17/25 June 17, 2025 1 EN
 PRESS RELEASE
Free
OXB Oxford BioMedic...

AGM Update

AGM Update Oxford, UK – 11 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, provides an update to coincide with its Annual General Meeting being held at 3pm BST today at Windrush Court, Oxford, UK. OXB has demonstrated strong commercial momentum and made good operational and commercial progress in the year 2025 to date, as it continues to provide viral vector manufacturing services to a diversified portfolio of clients. The Company remains on track to deliver the outlook set out in the Preliminary Results for the year ended 31 Decem...

June 11, 2025 1 EN
 PRESS RELEASE
Free
OXB Oxford BioMedic...

OXB Highlights the Launch of its Innovation and Technology Excellence ...

OXB Highlights the Launch of its Innovation and Technology Excellence Board Oxford, UK – 03 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today highlights the launch of its Innovation and Technology Excellence Board (ITEB). The ITEB brings together leading experts in cell and gene therapy, scientific innovation, and advanced manufacturing. It will advise OXB on technology priorities, innovation opportunities and emerging trends that support the Company’s growth as a pure-play CDMO. The newly formed advisory board, which held ...

June 3, 2025 1 EN
 PRESS RELEASE
Free
OXB Oxford BioMedic...

OXB to Present at the 28th Annual Meeting of the American Society of G...

OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Oxford, UK – 9 May 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place from 13–17 May 2025 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The Company will exhibit at Booth #1611, where delegates can meet OXB’s...

May 9, 2025 1 EN
 PRESS RELEASE
Free
OXB Oxford BioMedic...

Preliminary results for the year ended 31 December 2024

Preliminary results for the year ended 31 December 2024 ~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of 44% to £128.8 million compared to 2023, organic revenue growth of 81%1Operating EBITDA2 loss of £(15.3) million for the full year in line with expectations, Operating EBITDA profit of £5.0 million achieved in second half of 2024 Contracted value of client orders3 signed during 2024 reached approximately £186 million at 31 December 2024, an increase of c.35% compared to £138 million i...

April 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch